

Thalassemia testing. Simplified.



Comprehensive NGS testing for thalassemia and sickle cell disease. Now with β -modifier detection, robust CNV analysis, and a streamlined workflow.

Devyser Thalassemia v2 is a first-of-its-kind CE-marked (IVDR) NGS solution for comprehensive genetic testing in sickle cell disease and alpha- and beta-thalassemia. It identifies SNVs, indels, CNVs, challenging α -globin deletions, and clinically relevant β -globin modifiers, enabling fast, robust, and clinically meaningful results for diagnostic laboratories.

Broad coverage and comprehensive detection

- Broad coverage of HBA1/2, HBB, HBD, and HBG1/2, including SNVs, indels, CNVs, and complex deletions
- Direct detection of α 3.7 and α 4.2 deletions helps reduce reruns and improve result reliability

Efficient NGS workflow, built for reliable results

- Minimal hands-on time with a simple two-tube workflow and same-day library preparation

Dedicated analysis pipeline

- Integrated analysis pipeline for Devyser Thalassemia v2, enabling intuitive review and rapid reporting
- Ease-of-use removes in-house bioinformatics need


With their second version of the assay, Devyser has made testing for thalassemia even more robust and easy.

Dr. C.L. (Kees) Harteveld

Dpt of Clinical Genetics/Genome Diagnostics,

Hemoglobinopathy Expert Center of the Leiden University Medical Center, Leiden, The Netherlands

Simple NGS workflow



Dvyser®

Devyser – a new level of certainty

@Devyser
www.devyser.com

Dedicated analysis pipeline, straightforward to use

A dedicated analysis pipeline enables intuitive variant review and rapid, two-click report generation, minimizing the need for in-house bioinformatics expertise. The pipeline supports easy visualization of SNVs, CNVs, and modifier variants, and helps reduce manual data handling.

CNV overview: copy number profile across globin gene clusters with thresholds and confidence indicators. Calls summarized per sample for quick review.

Variant summary: consolidated view of SNVs, indels, CNVs, and modifier variants to support efficient interpretation and reporting.

Performance at a glance*

>97.6%

PPA

Positive percent agreement

>99.9%

NPA

Negative percent agreement

>99.9%

OPA

Overall percent agreement

*Clinical performance evaluated on 433 samples (426 residual clinical gDNA from individuals tested for suspected thalassemia or sickle cell disease + 7 cell-line gDNA samples) at two external ISO 15189-accredited European laboratories.

Sickle cell disease

Now validated for genetic testing in sickle cell disease, in addition to alpha- and beta thalassemia.



Contact us to get up and running faster:
Devysr Thalassemia v2 is available with leasing options for compatible Illumina sequencers.

Disclaimer: Devysr products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.

Devysr®

Devysr – a new level of certainty

Article numbers

Devysr Thalassemia v2 (CE-IVDR)

- 24 tests (8-R117-24)
- 48 tests (8-R117-48)

Amplicon Suite for Devysr Thalassemia v2

- 24 tests (8-C307-24)
- 48 tests (8-C307-48)

Check regulatory status in your country

Accessories

- Devysr Index Plate A (8-R200)
- Devysr Index Plate LB-A (8-R202)
- Devysr Index Plate LB-192 (8-R207)
- Devysr Library Clean (8-R204)

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx